Send me real-time posts from this site at my email

April 20-b - Trading List: Updates, Analyst Actions, Our Take - TGTX

TG Therapeutics initiated with a Neutral at Goldman Sachs

Goldman Sachs analyst Graig Suvannavejh initiated coverage of TG Therapeutics with a Neutral rating and $50 price target. The analyst sees "risk in small company product launches" and has a below consensus view on the company's 2021-2024 product sales. As such, he prefers to take a "wait and see approach" on the launches.

Our Take:  "We think this analyst is off the mark by a bit. See the earlier 2 analysts price raises and outlook from yesterday. This is still our Top Pick. A very good entry point right now."

$TGTX, TG Therapeutics, Inc. / H1

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so)!

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page.


Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue